等待开盘 07-18 09:30:00 美东时间
+0.342
+4.51%
Boston, July 8, 2025 - CervoMed Inc. (NASDAQ: CRVO) announced it will present results from the Phase 2b RewinD-LB study of neflamapimod for dementia with Lewy bodies (DLB) at the Alzheimer’s Association International Congress 2025 in Toronto. The presentations will include new findings and will be available both virtually and in-person. For more details, visit the Investor section of CervoMed’s website. Neflamapimod is an investigational drug tar...
07-08 11:00
CervoMed ( ($CRVO) ) has shared an update. On June 23, 2025, CervoMed Inc. held...
06-26 05:29
(转自:药研网) 6月24日,百奥泰宣布抗VEGF人源化单抗BAT5906针对新生血管性年龄相关性黄斑变性(w-AMD)的关键注册III期临床研究成功达到预设的...
06-24 17:59
CervoMed has appointed Marco Verwijs, PhD, as Executive Vice President of Technical Operations to oversee its CMC division and advance the development of neflamapimod through Phase 3 testing. Dr. Verwijs, with extensive experience in drug development, will help prepare for commercial manufacturing and a Phase 3 trial in dementia with Lewy Bodies (DLB) set to begin mid-2026. The company also granted him stock options as part of his employment indu...
06-10 12:00
(转自:药剂Talks) 一石激起千层浪。 5月20日,辉瑞以总金额高达60.5亿美元引进三生制药PD-1/VEGF双抗SSGJ-707在全球(不包括中国内地...
05-22 08:51
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行:维持Disc Medicine(IRON)"跑赢大市"评级,目标价从112美元升至120美元</p> <p>• 巴克莱:维持Karyopharm Therapeutics(KPTI)"超配"评级,目标价从5美
05-14 08:48
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital:维持Medicus Pharma(MDCX)"买入"评级,目标价从14美元升至27美元</p> <p>• 蒙特利尔银行:维持Disc Medicine(IRON)"跑赢大市"评级,目标价从
05-13 08:50
Chardan Capital analyst Daniil Gataulin maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $14 to $15.
05-13 06:04
CervoMed ( ($CRVO) ) has shared an announcement. On May 12, 2025, CervoMed Inc....
05-13 05:13
CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.66) by 15.15 percent. This is a 36.59 percent decrease over losses of $(0.41) per share from the same
05-12 20:04